These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 18449827)

  • 21. Poly-L-lactic acid: a new dimension in soft tissue augmentation.
    Rotunda AM; Narins RS
    Dermatol Ther; 2006; 19(3):151-8. PubMed ID: 16784514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of poly-L-lactic acid injections in persons with HIV-associated lipoatrophy: the US experience.
    Mest DR; Humble G
    Dermatol Surg; 2006 Nov; 32(11):1336-45. PubMed ID: 17083585
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Poly-L-lactic acid as a facial filler.
    Sterling JB; Hanke CW
    Skin Therapy Lett; 2005 Jun; 10(5):9-11. PubMed ID: 15986083
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized, multicenter, open-label study of poly-L-lactic acid for HIV-1 facial lipoatrophy.
    Carey DL; Baker D; Rogers GD; Petoumenos K; Chuah J; Easey N; Machon K; Cooper DA; Emery S; Carr A;
    J Acquir Immune Defic Syndr; 2007 Dec; 46(5):581-9. PubMed ID: 18193500
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Minimizing adverse events associated with poly-L-lactic acid injection.
    Narins RS
    Dermatol Surg; 2008 Jun; 34 Suppl 1():S100-4. PubMed ID: 18547172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Poly-L-lactic acid for the treatment of trauma-induced facial lipoatrophy and asymmetry.
    Rendon MI; Keeling J
    Cutis; 2008 Mar; 81(3):218-22. PubMed ID: 18441843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Poly-L-lactic-acid filling of facial lipoatrophy in HIV+ patients under tritherapy].
    Thiéry G; Coulet O; Adam S; Guyot L
    Rev Stomatol Chir Maxillofac; 2008 Apr; 109(2):103-5. PubMed ID: 18374957
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Poly-L-lactic acid for facial lipoatrophy in HIV.
    El-Beyrouty C; Huang V; Darnold CJ; Clay PG
    Ann Pharmacother; 2006 Sep; 40(9):1602-6. PubMed ID: 16912248
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA.
    Valantin MA; Aubron-Olivier C; Ghosn J; Laglenne E; Pauchard M; Schoen H; Bousquet R; Katz P; Costagliola D; Katlama C
    AIDS; 2003 Nov; 17(17):2471-7. PubMed ID: 14600518
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The evolution of injectable poly-L-lactic acid from the correction of HIV-related facial lipoatrophy to aging-related facial contour deficiencies.
    Burgess C
    J Drugs Dermatol; 2011 Sep; 10(9):1001-6. PubMed ID: 22052268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Poly-L-lactic acid: an overview.
    Simamora P; Chern W
    J Drugs Dermatol; 2006 May; 5(5):436-40. PubMed ID: 16703779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term effect of polyalkylimide gel injections on severity of facial lipoatrophy and quality of life of HIV-positive patients.
    Karim RB; de Lint CA; van Galen SR; van Rozelaar L; Nieuwkerk PT; Askarizadeh E; Hage JJ
    Aesthetic Plast Surg; 2008 Nov; 32(6):873-8. PubMed ID: 18551339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of Sculptra: a review of clinical trial data.
    Engelhard P; Humble G; Mest D
    J Cosmet Laser Ther; 2005 Dec; 7(3-4):201-5. PubMed ID: 16414909
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [L-polylactic acid].
    Taéron C
    Rev Infirm; 2005 Dec; (116):35-6. PubMed ID: 16454008
    [No Abstract]   [Full Text] [Related]  

  • 35. Caring for HIV-positive and aging patients with associated facial lipoatrophy.
    Esch P
    Plast Surg Nurs; 2006; 26(1):17-23. PubMed ID: 16543853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of polylactic acid implants to correct facial lipoatrophy in human immunodeficiency virus 1-positive individuals receiving combination antiretroviral therapy.
    Cattelan AM; Bauer U; Trevenzoli M; Sasset L; Campostrini S; Facchin C; Pagiaro E; Gerzeli S; Cadrobbi P; Chiarelli A
    Arch Dermatol; 2006 Mar; 142(3):329-34. PubMed ID: 16549708
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Injectable poly-L-lactic acid for cosmetic enhancement: learning from the European experience.
    Butterwick K; Lowe NJ
    J Am Acad Dermatol; 2009 Aug; 61(2):281-93. PubMed ID: 19615539
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cosmetic use of poly-l-lactic acid: a retrospective study of 130 patients.
    Palm MD; Woodhall KE; Butterwick KJ; Goldman MP
    Dermatol Surg; 2010 Feb; 36(2):161-70. PubMed ID: 20039924
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimizing poly-L-lactic acid use.
    Lowe NJ
    J Cosmet Laser Ther; 2008 Mar; 10(1):43-6. PubMed ID: 18330797
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of facial lipoatrophy in HIV-infected patients.
    Prescrire Int; 2008 Aug; 17(96):170. PubMed ID: 19492497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.